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by"multiple" subclones" genetically" heterogeneous" has" been" increasingly" considered" in" recent"
studies" as" an" element" of" particular" importance." This" feature" seems" to" influence" factors" as"
relevant"as"the"representativeness"of"tumour"biopsies"for"genetic"diagnosis"and"the"efficacy"of"
targeted" therapies." There" is" growing" evidence" suggesting" a" relation" between" genetic"
heterogeneity"and"the"patients’"prognosis."The"widespread"use"of"nextEgeneration"sequencing"
techniques"will" allow" a" better" understanding" of" the" true" degree" of" genetic" heterogeneity" in"
colorectal" tumours," its" causes" and" impact" on" the" course" of" the" disease." In" this" review" we"






Apesar" dos" recentes" avanços" no" desenvolvimento" de" métodos" complementares" de"
diagnóstico" e" de" novas" terapêuticas" dirigidas," o" carcinoma" coloErectal" continua" a" ser" uma"
importante" causa" mundial" de" morbilidade" e" mortalidade." Neste" sentido," têm" sido"
desenvolvidos"nos"últimos"anos"inúmeros"trabalhos"de"investigação"com"o"intuito"de"encontrar"
possíveis" marcadores" de" mau" prognóstico" ainda" não" caracterizados." A" existência" de" uma"
arquitectura" tumoral"complexa" formada"por"vários"subclones"com"heterogeneidade"genética"
entre" si" tem" sido" consistentemente" apontada" em" linhas" de" investigação" recentes" como" um"
elemento"de"particular"importância."Esta"característica"parece"ter"implicações"em"factores"tão"







na" evolução" da" doença." Nesta" revisão" pretendemos" analisar" as" recentes" descobertas"














Colorectal" carcinoma" is" an" important" cause" of" global" morbidity" and" mortality." Its"
aetiology" is" connected" to" sporadic" and" hereditary" genetic" alterations" in" connection" with"
environmental" factors," such" as" dietary" composition1." According" to" statistics" from" the"
International"Agency"for"Research"on"Cancer"through"the"GLOBOCAN"series,"colorectal"cancer"
is"the"third"most"frequent"type"of"cancer"in"men"(approximately"10.0%"of"all"cancers)"and"the"
second" in" women" (9.2%" of" total)" worldwide," with" the" majority" of" cases" taking" place" in"
developed" countries2." In" 2012" this" neoplasm"was" responsible" for" 694,000" deaths2," being" its"
mortality"correlated"with"the"stage"of" the"cancer"at" the"moment"of"diagnosis."Data" from"the"
American"Cancer"Society"shows"that"the"fiveEyear"survival"rate"in"colorectal"cancers"diagnosed"
at" a" localized" stage" is" about" 90%,"whereas" cancers"with" distant"metastases" at" diagnosis" see"
their" rate" drop" to" 13%3." Such" values" highlight" the" importance" of" implementing" national"
screening" programs" for" the" early" detection" of" colorectal" cancers,"whose" advantages" for" the"
population"health"have"been"confirmed"in"several"studies4.""
Despite"the"development"of"modern"diagnostic"and"treatment"technologies"as"well"as"
advances" in" pharmacogenomics," colorectal" carcinoma" is" still" a" major" burden" worldwide."














classification" of" cancers" by" pathologists5." Nowadays," due" to" this" intraEtumour" diversity" it" is"
common"practice"among"pathologists"to"evaluate"several"samples"of"one"tumour,"attributing"it"
the" highest" grade"observed6." In" fact," it" has" been" considered" for" some" time" that" cancers" are"
originated" from" distinct" subclones" that" accumulate" somatic"mutations" and" are" subjected" to"
5"
"
Darwinian" processes" of" natural" selection7." Recent" studies" have" confirmed" the" existence" of"
independent" evolution" of" clones" in" the" colon" as" soon" as" the" stage" of" microadenoma" and"
throughout" adenoma" development" until" the" adenomaEtoEcarcinoma" transition8," suggesting"
that" colorectal" tumorigenesis" is" a" process" characterised" by" polyclonality" and" a" branched"
evolution" of" clones." This" eventually" originates" the" emergence" of" a" complex" tumour"
architecture" constituted" by" intermingled" genetically" distinct" clones9." In" terms" of" DNA" copy"
number,"it"has"been"demonstrated"that"such"intraEtumour"heterogeneity"can"mirror"the"level"
of" heterogeneity" between" different" tumours10." However," as" far" as" genetic" variability" is"
concerned," the" degree" of" heterogeneity" within" individual" tumours" does" not" display" such"
extreme"values,"as"will"be"posteriorly"outlined."
There"has"been"accumulating"evidence"reinforcing"this"concept"of"branched"evolution"




apoptotic" machinery," some" neoplastic" cells" avoid" being" eliminated" by" increasing" their"
mutation"rate"and"accumulating"random"mutations15."This"increase"in"the"mutational"load"may"
grant" them"characteristics" that"will"make" them"more" fit" to"confront" the"pressures"of"natural"
selection16"and"may"lead"to"the"emergence"of"clones"with"increased"proliferative"advantage16."
Nonetheless," most" cancer" cells" do" not" develop" such" advantages" and" eventually" die" before"
dividing,"which"partially"explains"the"fact"that"tumours’"doubling"time"are"usually"much"longer"
than"the"cancer"cell"cycle"time9."
The" existence" of" genomic" instability" is" likely" to" be" a" significant" cause" of" genetic"
heterogeneity" as" well." Indeed" its" exact" impact" might" be" underestimated" due" to" the"
impossibility" of" evaluating" the" mutational" landscape" of" every" single" tumour" cell17."
Nevertheless,"it"must"be"taken"into"account"that"different"instability"mechanisms"are"related"to"
distinct" patient" outcomes." Specifically," colorectal" tumours" with" microsatellite" instability"
correlate" with" good" clinical" prognosis17." There" is" not" a" definite" explanation" for" this" fact."













tumours" and" its" related" metastases." Such" finding" can" happen" in" case" the" metastases" are"
originated"from"a"minor"subclone"not"easily"detected"in"biopsy"samples"of"the"primary"tumour"
or" in" view" of" a" parallel" progression" model" of" the" metastases" in" relation" to" the" primary"
tumour20." In" fact," some"minor" subclones"might"have"a"higher"ability" to"metastasize" than" the"
majority" of" other" cells" in" the" primary" tumour." This" can" lead" to" the" selection" of" a" specific"
mutational"load"in"the"metastases"and"thus"to"a"certain"degree"of"heterogeneity"21.""
One"important"feature"that"may"also"play"a"significant"role"in"the"development"of"this"
kind" of" genetic" heterogeneity" is" the" microenvironment22,23." In" order" to" adapt" to" a" dynamic"
microenvironment,"the"tumour"may"need"to"change"its"genetic"composition"both"at"different"
times" and" locations6,21."Moreover," the" fact" that" the"microenvironment" in"which" the" primary"
tumour" and" its" metastasis" are" located" might" be" different" could" lead" to" the" outgrowth" of"
metastatic"cells"with"a"mutational"load"distinct"from"the"primary"tumours,"as"a"way"to"adapt"to"
different" selection" pressures16." The" stroma" and" the" vascular" supply" are" two" environmental"
factors"particularly"relevant"in"the"development"of"a"tumour"mass"that"may"display"significant"
variations" between" different" locations," thereby" inducing" the" emergence" of" genetic"
heterogeneity" between" primary" tumours" and" its" associated" metastases18." The" stroma" is"
nowadays" recognized" as" an" important" part" of" tumours," making" it" necessary" to" approach"
carcinomas" as" functional" organs" and" not" just" a" group" of" neoplastic" cells18." In" fact," cancerE
associated" fibroblasts" have" characteristics" that" differentiate" them" from" regular" fibroblasts18,"
and"may"act"as"a"relevant"factor"in"treatment"response24."Moreover," it" is"believed"that"minor"
subclones" can" interact" with" other" subclones" through" the" release" of" paracrine" factors" that"
induce" their" growth," maintaining" the" intraEtumour" heterogeneity25" and" reinforcing" the" idea"
that"tumours"are"more"than"just"a"mass"of"cells."
The" distribution" of" tumour" vessels" is" also" an" important" source" of" tumour"
heterogeneity."Regions"of"hypoxia"within" a" tumour"or" a"metastasis" are" a" source"of" selective"
pressure" that" can" induce" the" emergence" of" clones" harbouring" mutations" that" grant" them"
survival"advantages18."Furthermore,"the"tumour"vasculature"is"also"a"determining"factor"in"the"













The" previously" described" causes" of" tumour" heterogeneity" impose" relevant" questions"
related" to" whether" or" not" biopsy" samples" are" illustrative" of" the" overall" genetic" content" of"
tumours."When"it" is"necessary"to"evaluate"the"presence"of"mutations"in"a"tumour"the"clinical"
routine" is" to" study" the"mutational" status" of" only" one" neoplastic" location."Until" this"moment"
there" is" no" formal" indication" as" to"which" samples" are"more" adequate" to" be" tested:" primary"
tumour," lymph" nodal" or" distant" metastases." Nevertheless," there" have" been" recent" findings"
regarding" genetic" heterogeneity" in" colorectal" cancer" that"must" be" taken" into" account" in" the"
future.""
First" of" all," the" presence" of" intraEtumour" heterogeneity" may" be" responsible" for" the"
existence" of" contradictory" results" in" the" mutation" analysis" of" resected" tumours" when"
compared"with"biopsies."Although"recent"studies"have"demonstrated"that"biopsy"samples"are"
“sufficiently"representative31"of"the"whole"tumour"and"that"they"can"be"used"with"efficacy" in"





Secondly," it" has" been" found" that" the" tumour" centre" has" a" higher" rate" of" KRAS"
mutations"when"compared"to"its"invasion"front35."Moreover,"recent"data"suggested"that"lymph"
nodal"metastases" are" not" as" suitable" as" primary" tumour" samples" and" distant"metastases" to"
assess" the" mutational" status" of" a" neoplastic" disease35" as" they" have" an" inferior" and" more"
heterogeneous"amount"of"mutations35,36." In"fact," it"has"been"proposed"that"nodal"metastases"
could"be"originated" in"a"disease" stage"prior" to" the"acquisition"of"KRAS"mutations"by"primary"
tumours36."
Finally,"in"case"of"a"clinical"relapse"the"usual"procedure"is"to"take"into"consideration"the"








in" every" patient’s" cancer" because" even" a" small" degree" of" mutational" discordance" between"
primary" tumours" and" metastases" may" lead" to" an" unreliable" diagnosis" and" misselection" of"
treatments."With"the"advent"of"personalized"medicine"there"has"been"an"increasing"interest"in"
the" research"and"clinical"use"of" therapies"molecularly"directed" to" specific" targets." This" is" the"
case" of" monoclonal" antibodies" to" epidermal" growth" factor" receptor" (EGFR)," cetuximab" and"
panitumumab,"in"colorectal"cancer38."These"antibodies"are"approved"for"the"treatment"of"KRAS"
wildEtype"metastatic" colorectal" cancer," and" they"were" the" first" treatment" for" solid" tumours"
whose"approval"depends"on"a"genetic"test38.""
In" fact," it" has" been" shown" in" several" studies" that" only" patients"with"wildEtype" KRAS"
have" substantial" clinical" response" rates" (up" to"50%"of" all" patients),"while"patients"with"KRAS"
mutated"tumours"only"have"effective"responses"in"a"maximum"of"6%"of"all"cases39E43."Although"
only"KRAS"and"NRAS"mutations"are"used"routinely"as"exclusion"criteria"for"the"use"of"antiEEGFR"
monoclonal"antibodies,"mutations" in"other"EGFREdependent" signalling"molecules"may" induce"
resistance"to"the"treatment." It"has"been"estimated"that" it"would"be"possible"to"identify"up"to"
15%"more"refractory"cases"to"this"treatment"if"mutation"analyses"for"BRAF"and"PIK3CA"was"to"
be" introduced" in"clinical"practice35."Despite"what"could"be"expected," the"expression" levels"of"
EGFR" do" not" seem" to" have" a" predictive" value" in" the" therapeutic" response" to" these"
antibodies44,45."As"a"matter"of"fact,"it"has"been"found"that"tumours"classified"as"EGFREnegative"
by" immunohistochemistry" have" the" potential" to" respond" in" up" to" 25%" of" all" cases46." Such"




metastatic" and" primary" tumour" samples," which" translates" in" suboptimal" treatment" of"
metastatic"disease16."Many"studies"have"reported"incongruous"determinations"of"prognostic"or"
predictive" biomarkers" between" primary" tumours" and" distant" metastases" in" several" tumour"
models."However," the"average"degree"of"heterogeneity" is"difficult" to"estimate"with"accuracy"
because" of" methodological" and" sampling" limitations." Specifically" in" colorectal" cancer," the"
values"of"disparity"for"KRAS"mutations"(used"as"a"predictive"biomarker"of"response"to"directed"
therapies)"between"primary"tumours"and"metastases"in"different"studies"has"ranged"from"0%"




metastases" should" be" preferentially" studied" when" the" use" of" targeted" therapies" is" being"
considered21." This"procedure" is,"however," associated"with"higher" risk"of" complications"and" is"
not"usually"performed"in"clinical"practice."On"the"other"hand,"there"is"an"increasing"number"of"
recent" studies" reporting"a"degree"of"concordance"between"primary" tumours"and"metastases"
higher" than" 95%21,48E52," one" of" these" studies" using" nextEgeneration" sequencing" techniques."
Therefore,"it"has"been"proposed"that"the"metastases"should"only"be"biopsied"in"patients"with"
more"than"one"primary"cancer50."
A" better" understanding" of" the"mechanisms" that" induce" tumour" heterogeneity" could"
improve" the" management" of" cancer" patients" and" probably" help" to" predict" treatment"
resistance."Some"mechanisms"of"therapeutic"resistance"are"well"defined"and"involve"secondary"
genetic"alterations"that"restrict"the"binding"of"drugs"to"their"targets"or"induce"the"activation"of"
alternative" pathways16,20." However," many" mutations" that" induce" resistance" to" targeted"
therapies"may"exist"prior"to"the"start"of"the"treatment"in"minor"subclones."Those"may"emerge"
and"become"dominant"due"to"the"selective"pressures"of"the"target"therapies20." In"the"case"of"
colorectal" cancer," circulating" DNA" tumour" with" KRAS" mutations" can" be" detected" in" some"
patients" 5" to" 6" months" after" treatment" with" antiEEGFR" antibody" therapy53," reinforcing" the"
possible" existence" prior" to" treatment" of"minor" subclones" harbouring"mutations" that" induce"
resistance"to"directed"therapies."""
Therefore," the" degree" of" genetic" diversity" between" tumour" cells" could" be" fairly"
informative" and" if" properly" measured" this" information" could" be" used" with" therapeutic"
advantage."The"“trunkEbranch"model”"of" tumour"heterogeneity,"documented"by"Gerlinger"et"
al.12," demonstrates" that" “driver" mutations”" in" the" trunk" are" the" ones" for" which" treatments"




In" the" near" future" of" personalized" medicine," the" improvement" of" sequencing"
technologies"will"allow"the"detection"of"mutations"only"expressed"by"a"minority"of"cells"before"
the" start" of" treatment" and" will" eventually" lead" to" the" use" of" a" combination" of" successful"
therapies," targeting" multiple" signalling" pathways" simultaneously." Besides," developing"
techniques" to" analyse" cellEfree" circulating" tumour" DNA" and" circulating" tumour" cells" would"








The" vast"majority" of" advanced" and"metastatic" cancers" are" still" incurable" despite" the"
remarkable"advances"in"translational"and"clinical"research"in"the"last"decades."The"introduction"
of" molecularEtargeted" drugs" has" considerably" enhanced" the" outcome" of" patients" with" solid"
tumours" in"advanced"stages."However,"not"all"molecularly"selected"patients"will"demonstrate"




of" identifying" mutations" that" are" only" expressed" in" minor" clones," and" therefore" less"
represented"in"the"whole"tumour,"is"gradually"becoming"a"reality16."This"way"it"will"be"possible"
to" effectively" assess" the" overall" mutational" landscape" of" tumours" in" the" near" future54" thus"
increasing" our" ability" to" evaluate" the" degree" of" intra" and" interEtumour" heterogeneity" of" a"
single"patient6.""In"order"to"ensure"the"reliability"of"results"achieved"through"these"techniques"
the"Next"Generation"Sequencing"Standardization"of"Clinical"Testing"workgroup"advocates"that"
all" mutations" with" clinical" implications" should" be" corroborated" by" alternative" methods55."
However,"in"the"case"of"lowEfrequency"mutations"representative"of"minor"subclones,"it"might"
not"be"possible"to"do"so"by"Sanger"or"PCR"sequencing37."Furthermore,"such"procedure"poses"a"
problem" related" to" how" long" do" oncologists" and" patients" consider" adequate" to"wait" for" the"
result"of"genetic"diagnostics"before"initiating"a"treatment37."
Finally,"there"is"an"issue"that"must"be"considered"when"conducting"research"to"assess"
intraEtumour" heterogeneity." Transplantation" assays" in" animal" models" have" been" used" in"
several" studies" to" examine" genetic" heterogeneity" in" different" types" of" cancer" and" have"
generated" numerous" and" sometimes" contradictory" results." However," such" reports" must" be"
cautiously" interpreted" considering" that" they"may" possibly" not" resemble"with" accuracy"what"
happens"in"human"tumours56."In"fact,"xenotransplanted"tumours"might"not"express"to"the"full"
extent" their" growth" potential" due" to" mice’s" immune" system" response56" and" may" also" not"
recreate" the"structure"of" functional" tissues"due"to" inadequate"stromal"environment56."For"all"



















5." Hajdu" SI." A" note" from" history:" landmarks" in" history" of" cancer," part" 3." Cancer"
2012;118:1155E68."
6." Fisher" R," Pusztai" L," Swanton" C." Cancer" heterogeneity:" implications" for" targeted"
therapeutics."Br"J"Cancer"2013;108:479E85."
7." Nowell"PC."The"clonal"evolution"of"tumor"cell"populations."Science"1976;194:23E8."
8." Thirlwell" C,"Will"OC,"Domingo" E,"Graham"TA,"McDonald" SA,"Oukrif"D," et" al." Clonality"
assessment"and"clonal"ordering"of" individual"neoplastic" crypts" shows"polyclonality"of"
colorectal"adenomas."Gastroenterology"2010;138:1441E54,"54.e1E7."
9." Greaves"M,"Maley"CC."Clonal"evolution"in"cancer."Nature"2012;481:306E13."
10." Martinez" P," Birkbak" NJ," Gerlinger" M," McGranahan" N," Burrell" RA," Rowan" AJ," et" al."









14." Hanahan" D," Weinberg" RA." Hallmarks" of" cancer:" the" next" generation." Cell"
2011;144:646E74."
15." Loeb"LA."Cancer"cells"exhibit"a"mutator"phenotype."Adv"Cancer"Res"1998;72:25E56."








19." Fridman"WH,"Pages" F," SautesEFridman"C,"Galon" J." The" immune" contexture" in"human"
tumours:"impact"on"clinical"outcome."Nat"Rev"Cancer"2012;12:298E306."
20." Marusyk" A," Almendro" V," Polyak" K." IntraEtumour" heterogeneity:" a" looking" glass" for"
cancer?"Nat"Rev"Cancer"2012;12:323E34."
21." Vermaat" JS," Nijman" IJ," Koudijs" MJ," Gerritse" FL," Scherer" SJ," Mokry"M," et" al." Primary"
colorectal" cancers"and" their" subsequent"hepatic"metastases"are"genetically"different:"
implications" for" selection" of" patients" for" targeted" treatment." Clin" Cancer" Res"
2012;18:688E99."





stromal" fibroblasts" increases" invasiveness" of" pancreatic" cancer" cells" through" tumorE
stromal"interactions."Cancer"Res"2004;64:3215E22."
25." Inda" MM," Bonavia" R," Mukasa" A," Narita" Y," Sah" DW," Vandenberg" S," et" al." Tumor"
heterogeneity" is" an" active" process" maintained" by" a" mutant" EGFREinduced" cytokine"
circuit"in"glioblastoma."Genes"Dev"2010;24:1731E45."
26." Tredan" O," Galmarini" CM," Patel" K," Tannock" IF." Drug" resistance" and" the" solid" tumor"
microenvironment."J"Natl"Cancer"Inst"2007;99:1441E54."
27." Des" Guetz" G," Uzzan" B," Nicolas" P," Cucherat" M," Morere" JF," Benamouzig" R," et" al."
Microvessel"density" and"VEGF"expression"are"prognostic" factors" in" colorectal" cancer."
MetaEanalysis"of"the"literature."Br"J"Cancer"2006;94:1823E32."
28." Mao"Q,"Zhang"Y,"Fu"X,"Xue"J,"Guo"W,"Meng"M,"et"al."A"tumor"hypoxic"niche"protects"





30." Hurwitz" HI," Fehrenbacher" L," Hainsworth" JD," Heim" W," Berlin" J," Holmgren" E," et" al."
13"
"
Bevacizumab" in" combination"with" fluorouracil" and" leucovorin:" an" active" regimen" for"
firstEline"metastatic"colorectal"cancer."J"Clin"Oncol"2005;23:3502E8."
31." Fadhil" W," Ibrahem" S," Seth" R," AbuAli" G," Ragunath" K," Kaye" P," et" al." The" utility" of"
diagnostic" biopsy" specimens" for" predictive" molecular" testing" in" colorectal" cancer."
Histopathology"2012;61:1117E24."
32." Krol"LC,"t"Hart"NA,"Methorst"N,"Knol"AJ,"Prinsen"C,"Boers"JE."Concordance"in"KRAS"and"
BRAF"mutations" in"endoscopic"biopsy" samples"and" resection" specimens"of" colorectal"
adenocarcinoma."Eur"J"Cancer"2012;48:1108E15."
33." Richman" SD," Chambers" P," Seymour" MT," Daly" C," Grant" S," Hemmings" G," et" al." IntraE
tumoral" heterogeneity" of" KRAS" and"BRAF"mutation" status" in" patients"with" advanced"











37." Bedard"PL,"Hansen"AR,"Ratain"MJ," Siu" LL."Tumour"heterogeneity" in" the"clinic."Nature"
2013;501:355E64."
38." Messersmith" WA," Ahnen" DJ." Targeting" EGFR" in" colorectal" cancer." N" Engl" J" Med"
2008;359:1834E6."
39." Lievre"A,"Bachet"JB,"Le"Corre"D,"Boige"V,"Landi"B,"Emile"JF,"et"al."KRAS"mutation"status"is"
predictive" of" response" to" cetuximab" therapy" in" colorectal" cancer." Cancer" Res"
2006;66:3992E5."
40." Lievre"A,"Bachet" JB,"Boige"V,"Cayre"A,"Le"Corre"D,"Buc"E,"et"al."KRAS"mutations"as"an"
independent" prognostic" factor" in" patients" with" advanced" colorectal" cancer" treated"
with"cetuximab."J"Clin"Oncol"2008;26:374E9."
41." Di"Fiore"F,"Blanchard"F,"Charbonnier"F," Le"Pessot"F," Lamy"A,"Galais"MP,"et"al."Clinical"
relevance" of" KRAS" mutation" detection" in" metastatic" colorectal" cancer" treated" by"
Cetuximab"plus"chemotherapy."Br"J"Cancer"2007;96:1166E9."
42." KhambataEFord" S," Garrett" CR," Meropol" NJ," Basik" M," Harbison" CT," Wu" S," et" al."
14"
"
Expression" of" epiregulin" and" amphiregulin" and" KEras"mutation" status" predict" disease"
control" in"metastatic" colorectal" cancer" patients" treated"with" cetuximab." J" Clin"Oncol"
2007;25:3230E7."
43." De"Roock"W,"Piessevaux"H,"De"Schutter"J,"Janssens"M,"De"Hertogh"G,"Personeni"N,"et"
al." KRAS" wildEtype" state" predicts" survival" and" is" associated" to" early" radiological"
response" in" metastatic" colorectal" cancer" treated" with" cetuximab." Ann" Oncol"
2008;19:508E15."
44." Saltz" LB,"Meropol"NJ," Loehrer" PJ," Sr.,"Needle"MN,"Kopit" J,"Mayer"RJ." Phase" II" trial" of"
cetuximab" in"patients"with" refractory" colorectal" cancer" that"expresses" the"epidermal"
growth"factor"receptor."J"Clin"Oncol"2004;22:1201E8."
45." Hecht"JR,"Mitchell"E,"Neubauer"MA,"Burris"HA,"3rd,"Swanson"P,"Lopez"T,"et"al."Lack"of"
correlation" between" epidermal" growth" factor" receptor" status" and" response" to"
Panitumumab" monotherapy" in" metastatic" colorectal" cancer." Clin" Cancer" Res"
2010;16:2205E13."
46." Chung" KY," Shia" J," Kemeny"NE," Shah"M," Schwartz" GK," Tse" A," et" al." Cetuximab" shows"
activity" in" colorectal" cancer" patients"with" tumors" that" do" not" express" the" epidermal"
growth"factor"receptor"by"immunohistochemistry."J"Clin"Oncol"2005;23:1803E10."
47." Stoecklein" NH," Klein" CA." Genetic" disparity" between" primary" tumours," disseminated"
tumour"cells,"and"manifest"metastasis."Int"J"Cancer"2010;126:589E98."
48." Knijn" N,"Mekenkamp" LJ," Klomp"M," VinkEBorger"ME," Tol" J," Teerenstra" S," et" al." KRAS"
mutation" analysis:" a" comparison" between" primary" tumours" and" matched" liver"
metastases"in"305"colorectal"cancer"patients."Br"J"Cancer"2011;104:1020E6."
49." Park"JH,"Han"SW,"Oh"DY,"Im"SA,"Jeong"SY,"Park"KJ,"et"al."Analysis"of"KRAS,"BRAF,"PTEN,"
IGF1R," EGFR" intron" 1" CA" status" in" both" primary" tumors" and" paired" metastases" in"














of" acquired" resistance" to" targeted" EGFR" blockade" in" colorectal" cancers." Nature"
2012;486:537E40."
54." Russnes" HG," Navin" N," Hicks" J," BorresenEDale" AL." Insight" into" the" heterogeneity" of"
breast"cancer"through"nextEgeneration"sequencing."J"Clin"Invest"2011;121:3810E8."
55." Gargis"AS,"Kalman"L,"Berry"MW,"Bick"DP,"Dimmock"DP,"Hambuch"T,"et"al."Assuring"the"
quality" of" nextEgeneration" sequencing" in" clinical" laboratory" practice." Nat" Biotechnol"
2012;30:1033E6."







Gostaria( de( aproveitar( esta( oportunidade( para( agradecer( a( algumas( pessoas( que(







disso( quero( expressar( o( meu( agradecimento( por( terem( confiado( no( meu( interesse( e(














um( sincero( obrigado( pelo( suporte( imprescindível( que( têm( sido( nos( bons( e( nos( maus(
momentos.( A( vossa( companhia( fez( com( que( os( obstáculos( deste( percurso( se( tenham(
transformado(em(desafios(que(ultrapassámos(em(conjunto.((
(
Aproveito(esta(oportunidade(para(expressar( a(minha(estima(por( toda(a( ajuda(que(











Penso(ser( justo(que(manifeste(a( relevância(de( todos(os(docentes(que(ao( longo(do(
meu(percurso(educativo,(universitário(mas(não(só,( tiveram(vocação(para(ensinar.(Gostaria(
de( destacar( o( Professor( Doutor( Sobrinho( Simões( pela( sua( sabedoria,( dinamismo( e(
humanidade(e(pela(forma(como(inspirou(em(mim(o(gosto(pela(Ciência.(
(
Por( fim,(vou(deixar(aqui(um(agradecimento(um(tanto( inusitado(a( todos(os(artistas(
que( ao( longo( dos( anos( me( inspiraram,( abriram( horizontes( intelectuais( e( fizeram( sonhar,(



























Normas de Publicação 
da Acta Médica Portuguesa
Acta Médica Portuguesa’s Publishing Guidelines
&RQVHOKR(GLWRULDO$&7$0e',&$32578*8(6$









































 Lema: ³3ULPXP QRQ QRFHUH SULPHLUR D $FWD 0pGLFD
3RUWXJXHVD´
4. INfORMAÇÃO GeRAL
 $$FWD 0pGLFD 3RUWXJXHVD p D UHYLVWD FLHQWt¿FD FRP
UHYLVmRSHORVSDUHVpeer-reviewGD2UGHPGRV0pGLFRV




 $ $FWD 0pGLFD 3RUWXJXHVD VHJXH D SROtWLFD GR OLYUH
DFHVVR 7RGRV RV VHXV DUWLJRV HVWmR GLVSRQtYHLV GH IRU-
PD LQWHJUDO DEHUWD H JUDWXLWD GHVGH  QR VHX VLWH 





 2V PDQXVFULWRV GHYHP VHU VXEPHWLGRV online via 
³6XEPLVV}HV2QOLQH´KWWSZZZDWDPHGLFDSRUWXJXHVDFRP 































UHSRVLWyULRV GDV VXDV LQVWLWXLo}HV GH RULJHP GHVGH TXH
PHQFLRQHPVHPSUHRQGHIRUDPSXEOLFDGRV



























H FRQWULEXLo}HV FRQÀLWRV GH LQWHUHVVH H ¿QDQFLDPHQWR H
WUDQVIHUrQFLDGHGLUHLWRVDXWRUDLVcopyright.






DWHVWDU DLQGD HPQRPHGH WRGRV RV FRDXWRUHV D RULJL-
QDOLGDGHGRWUDEDOKRHREWHUDSHUPLVVmRHVFULWDGHFDGD
SHVVRDPHQFLRQDGDQDVHFomR³$JUDGHFLPHQWRV´

















QmR LQIULQJH QHQKXPcopyright HQmR YLROD QHQKXPGLUHL-















7. CONfLItOS de INteReSSe
 2 ULJRU H D H[DFWLGmRGRV FRQWH~GRV DVVLPFRPRDV
RSLQL}HVH[SUHVVDVVmRGDH[FOXVLYDUHVSRQVDELOLGDGHGRV
$XWRUHV 2V$XWRUHV GHYHP GHFODUDU SRWHQFLDLV FRQÀLWRV





 (VVD LQIRUPDomR QmR LQÀXHQFLDUi D GHFLVmR HGLWRULDO
PDV DQWHV GD VXEPLVVmR GRPDQXVFULWR RV DXWRUHV WrP










PHQWR LQIRUPDGRSDUD GHVFULomRGHGRHQWHV IRWRJUD¿DH








































































































































GLFDSRUWXJXHVDFRP ³VXEPHWHU DUWLJR´ LQGLFDQGR FODUD-
PHQWHSRUTXH FRQVLGHUDPTXHRPDQXVFULWR p DGHTXDGR
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 F 3DODYUDVFKDYH Keywords 8P Pi[LPR GH 
Keywords HP LQJOrVXWLOL]DQGRD WHUPLQRORJLDTXHFRQVWD
QR0HGLFDO6XEMHFW+HDGLQJV0H6+KWWSZZZQOPQLK
JRYPHVK0%URZVHUKWPOGHYHPVHJXLUVHDRUHVXPR








 $UWLJRV HODERUDGRV DSHQDV SRU FRQYLWH GR &RQVHOKR
(GLWRULDO3RGHPFREULUJUDQGHGLYHUVLGDGHGHWHPDVFRP


























O Artigos Originais: 
 2 WH[WR GHYH VHU DSUHVHQWDGR FRPDV VHJXLQWHV VHF-














































 Caso Clínico: 












 Imagens em Medicina (Imagem Médica): 
 $,PDJHPHP0HGLFLQDpXPFRQWULEXWRLPSRUWDQWHGD
DSUHQGL]DJHP H GD SUiWLFD PpGLFD 3RGHUmR VHU DFHLWHV








 6y VmR DFHLWHV IRWRJUD¿DV RULJLQDLV GH DOWD TXDOLGD-
GHTXHQmRWHQKDPVLGRVXEPHWLGDVDSUpYLDSXEOLFDomR
'HYHP VHU HQYLDGRV GRLV ¿FKHLURV XP FRP D TXDOLGDGH





 Guidelines / Normas de orientação: 
 $V VRFLHGDGHVPpGLFDV RV FROpJLRV GDV HVSHFLDOLGD-
GHV DV HQWLGDGHV R¿FLDLV H  RX JUXSRV GHPpGLFRV TXH
GHVHMHPSXEOLFDUQD$FWD0pGLFD3RUWXJXHVDUHFRPHQGD-
o}HV GH SUiWLFD FOtQLFD GHYHUmR FRQWDFWDU SUHYLDPHQWH R
&RQVHOKR(GLWRULDOHVXEPHWHURWH[WRFRPSOHWRHDYHUVmR
SDUD VHU SXEOLFDGD2(GLWRU&KHIH SRGHUi FRORFDU FRPR





 Cartas ao editor: 
 'HYHP FRQVWLWXLU XP FRPHQWiULR D XP DUWLJR GD$FWD







H[SHULrQFLD SHVVRDO IRUQHFHU XPD V~PXOD FLWDU UHIHUrQ-
FLDV

























DEUHYLDWXUD HQWUH SDUHQWHVHV 1mR FRORTXH SRQWRV ¿QDLV
QDVDEUHYLDWXUDV




 $V WHPSHUDWXUDV GHYHP VHU GDGDV HP JUDXV &HOVLXV
&HDSUHVVmRDUWHULDOHPPLOtPHWURVGHPHUF~ULR PP
+J
 3DUDPDLV LQIRUPDomRFRQVXOWHD WDEHODGHFRQYHUVmR
³8QLWVRI0HDVXUH´QR websiteGD$0$0DQXDO6W\OH











 1RPDQXVFULWR VmR DFHLWiYHLV RV VHJXLQWHV IRUPDWRV
%03(36-3*3')H7,)FRPGSLVGH UHVROXomR
SHORPHQRVpixeisGHODUJXUDHDOWXUDSURSRUFLRQDO

































































































FHU D WRGRV RV TXH FRQWULEXtUDP SDUD R HVWXGRPDV QmR
WrPSHVRGHDXWRULD1HVWDVHFomRpSRVVtYHODJUDGHFHUD
WRGDVDVIRQWHVGHDSRLRTXHU¿QDQFHLURTXHUWHFQROyJLFR























 $V DEUHYLDWXUDV XVDGDV QD QRPHDomR GDV UHYLVWDV
GHYHPVHUDVXWLOL]DGDVSHOR1DWLRQDO/LEUDU\RI0HGLFLQH
1/0 Title Journals Abbreviations KWWSZZZQFELQOPQLK
JRYQOPFDWDORJMRXUQDOV
Notas1mRLQGLFDUPrVGDSXEOLFDomR
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